Novartis Sees Sales Growth Through 2031
By Adria Calatayud
Novartis forecast steady sales growth through 2031, citing momentum from drugs already in the market and upcoming launches, and said medicines it has in the pipeline would help it sustain growth over the long term.
The Swiss drugmaker said Thursday that it expects annual sales growth of 5% from 2026 to 2031, excluding the effect of currency movements. It had previously forecast annual sales growth in the 5% to 6% range over the 2025-30 period.
Novartis raised its peak sales estimates for key drugs Kesimpta, Scemblix and Leqvio, saying this reinforces confidence in the company's midterm outlook.
The company said it now has nine in-market products with potential to generate annual peak sales of between $3 billion and $10 billion, as well as 10 in late-stage development that could bring in multibillion-dollar sales at their peak.
Novartis also said it is on track to return to a core operating profit margin above 40% by 2029, as previously indicated.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
November 19, 2026 01:39 ET (06:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

The 10 Best Dividend Stocks

